Has BCG attenuated to impotence?

Marcel A. Behr and Peter M. Small
Additional contact information
Marcel A. Behr: Stanford University Medical Center
Peter M. Small: Stanford University Medical Center

Nature, 1997, vol. 389, issue 6647, 133-134

Abstract: Abstract The magnitude of the global tuberculosis problem and the emergence of antibiotic-resistant organisms has resulted in a renewed need for tuberculosis vaccine development. An ideal vaccine would consistentlyconfer protection without confoundingthe interpretation of the tuberculin skin test. The current vaccine, Bacille Calmette-Guérin (BCG), provides inconsistent efficacy (0-80% in randomized control trials) yet usually induces tuberculin reactivity. This variability in observed efficacy has been attributed to differences in trial methodology, host genetics and immunity to a variety of environmental mycobacteria1. We hypothesize that the attributes of the current BCG have resulted from subtlepressures to minimize adverse reactions and maintain tuberculin reactivity during vaccine development and testing.

Date: 1997
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/38151 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:389:y:1997:i:6647:d:10.1038_38151

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/38151

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().